Daily Stock Analysis, HTBX, Heat Biologics Inc, priceseries

Heat Biologics Inc. Daily Stock Analysis
Stock Information
Open
0.43
Close
0.43
High
0.46
Low
0.43
Previous Close
0.43
Daily Price Gain
-0.00
YTD High
1.80
YTD High Date
Feb 28, 2019
YTD Low
0.35
YTD Low Date
Oct 15, 2019
YTD Price Change
-0.63
YTD Gain
-59.27%
52 Week High
2.10
52 Week High Date
Nov 20, 2018
52 Week Low
0.35
52 Week Low Date
Oct 15, 2019
52 Week Price Change
-1.32
52 Week Gain
-75.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 12. 2017
5.70
Oct 11. 2017
6.90
21 Trading Days
21.09%
Link
LONG
Jan 4. 2019
1.07
Jan 24. 2019
1.33
13 Trading Days
23.96%
Link
Company Information
Stock Symbol
HTBX
Exchange
NasdaqCM
Company URL
http://www.heatbio.com
Company Phone
919-240-7133
CEO
Jeff A. Wolf
Headquarters
North Carolina
Business Address
801 CAPITOLA DRIVE, DURHAM, NC 27713
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001476963
About

Heat Biologics, Inc. operates as a clinical-stage biopharmaceutical company, with interest in the development of novel allergenic drugs. The company focuses on the commercialization of ImPact Therapy, a platform technology that offers a novel approach to treat cancer and other infectious diseases, including HIV, HCV and malaria by using live, genetically-modified, and irradiated human cells to activate the immune system against specific defined targets. Heat Biologics was founded on June 10, 2008 by Jeffrey Alan Wolf and is headquartered in Durham, NC.

Description

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.